Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL026
MIFTS: 68

Allergic Hypersensitivity Disease

Categories: Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Allergic Hypersensitivity Disease

About this section

MalaCards integrated aliases for Allergic Hypersensitivity Disease:

Name: Allergic Hypersensitivity Disease 12 15
Hypersensitivity 12 77 45 15 74
Allergy 12 56 6 44 17
Allergic Disposition 74
Allergic Condition 74
Allergic Reaction 74
Allergic Disease 12

Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1205
MeSH 45 D006967
NCIt 51 C3114
SNOMED-CT 69 21957007 91232002
ICD10 34 T78.4 T78.40
Sources

Summaries for Allergic Hypersensitivity Disease

About this section
MedlinePlus : 44 An allergy is a reaction by your immune system to something that does not bother most other people. People who have allergies often are sensitive to more than one thing. Substances that often cause reactions are Pollen Dust mites Mold spores Pet dander Food Insect stings Medicines Normally, your immune system fights germs. It is your body's defense system. In most allergic reactions, however, it is responding to a false alarm. Genes and the environment probably both play a role. Allergies can cause a variety of symptoms such as a runny nose, sneezing, itching, rashes, swelling, or asthma. Allergies can range from minor to severe. Anaphylaxis is a severe reaction that can be life-threatening. Doctors use skin and blood tests to diagnose allergies. Treatments include medicines, allergy shots, and avoiding the substances that cause the reactions. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Allergic Hypersensitivity Disease, also known as hypersensitivity, is related to cow milk allergy and cephalosporin allergy, and has symptoms including nausea and vomiting, abdominal pain and pruritus. An important gene associated with Allergic Hypersensitivity Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ertapenem and Alcaftadine have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and lung, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

Wikipedia : 77 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...

Sources

Related Diseases for Allergic Hypersensitivity Disease

About this section

Diseases related to Allergic Hypersensitivity Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1394)
# Related Disease Score Top Affiliating Genes
1 cow milk allergy 34.2 IL10 IL5 RNASE3
2 cephalosporin allergy 34.1 IFNG IL10 IL5
3 beta-lactam allergy 34.1 IL10 IL13 IL4
4 apple allergy 33.9 CCL17 IL10 IL13 IL4 IL5
5 respiratory allergy 33.5 CCL11 IGHE IL10 IL13 IL4 IL5
6 allergic contact dermatitis 32.7 CCL17 IFNG IL10 IL4 IL5
7 esophagitis, eosinophilic, 1 32.5 CCL11 IL13 IL5
8 blepharoconjunctivitis 32.5 CCL11 IL4 RNASE3
9 giant papillary conjunctivitis 32.4 CCL11 IL4 RNASE3
10 orofacial granulomatosis 32.2 CCL5 CCR3 IFNG IL10 IL4
11 sarcoidosis 1 32.2 CCL17 IFNG IL13 IL9
12 vernal keratoconjunctivitis 32.1 CCL11 CCL5 IL13 IL4 IL5 RNASE3
13 immune system disease 32.0 IFNG IL10 IL4 IL5
14 allergic conjunctivitis 32.0 CCL11 HRH1 IFNG IL13 IL4 IL5
15 autoimmune disease of central nervous system 31.8 CCL5 IFNG IL10 IL4
16 mycobacterium tuberculosis 1 31.4 IFNG IL10 IL4
17 contact dermatitis 31.3 CCL17 IFNG IL10 IL4 IL5
18 maxillary sinusitis 30.9 CCL5 RNASE3
19 eosinophilic gastroenteritis 30.8 CCL11 EPX IL5 RNASE3
20 gastroenteritis 30.7 CCL11 IL10 IL4 IL5 RNASE3
21 dermatitis 30.7 CCL11 CCL17 IFNG IGHE IL13 IL4
22 inflammatory bowel disease 30.7 IFNG IL10 IL13 IL4
23 tetanus 30.7 IFNG IL10 IL13 IL4 IL5
24 gastrointestinal system disease 30.7 CCL11 IFNG IL10
25 common cold 30.6 CCL11 CCL5 IL13 IL5 RNASE3
26 leishmaniasis 30.6 IFNG IL10 IL13 IL4 IL5
27 lung disease 30.6 CCL5 IL10 IL13 IL5 RNASE3
28 multiple sclerosis 30.6 CCL5 IFNG IL10 IL4
29 pulmonary fibrosis, idiopathic 30.5 CCL17 CCL5 IFNG IL13
30 food allergy 30.5 CSN1S1 EPX IFNG IL10 IL13 IL4
31 allergic bronchopulmonary aspergillosis 30.5 CCL17 EPX IL4 IL5
32 ige responsiveness, atopic 30.5 IFNG IGHE IL10 IL13 IL4 IL5
33 yellow fever 30.5 CCL5 IL4 IL5
34 paracoccidioidomycosis 30.5 IFNG IL10 IL4 IL5
35 aspergillosis 30.5 CCL17 IFNG IL10 IL4 IL5
36 brucellosis 30.4 IFNG IL10 IL4
37 pollen allergy 30.4 EPX IL13 IL5 RNASE3
38 cytokine deficiency 30.4 IL13 IL5 IL9
39 pneumonia 30.4 CCL11 CCL5 IL10 IL13 IL5
40 egg allergy 30.4 IGHE IL4 IL5
41 chlamydia 30.3 IFNG IL10 IL4
42 q fever 30.3 IFNG IL10 IL4
43 cutaneous leishmaniasis 30.3 FCER2 IFNG IL10 IL13 IL4 IL5
44 genital herpes 30.3 CCL5 IL10 IL4
45 hyper ige syndrome 30.2 IFNG IGHE IL4
46 eales disease 30.2 IFNG IL10 IL4
47 toxic shock syndrome 30.2 IFNG IL10 IL4
48 coccidiosis 30.2 IFNG IL10 IL4
49 common variable immunodeficiency 30.2 IFNG IL10 IL4 IL5
50 neuritis 30.2 CCL5 IFNG IL4

Graphical network of the top 20 diseases related to Allergic Hypersensitivity Disease:



Diseases related to Allergic Hypersensitivity Disease
Sources

Symptoms & Phenotypes for Allergic Hypersensitivity Disease

About this section

UMLS symptoms related to Allergic Hypersensitivity Disease:


nausea and vomiting, abdominal pain, pruritus, tinnitus, syncope, stridor, snoring, sore throat, exanthema, coughing, vertigo/dizziness, equilibration disorder, signs and symptoms of ill-defined conditions, (non-specific) malaise and fatigue, injection site hypersensitivity, fever of unknown origin

MGI Mouse Phenotypes related to Allergic Hypersensitivity Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CCL11 CCL17 CCL5 CCR3 EPX FCER2
2 digestive/alimentary MP:0005381 9.86 FCER2 IFNG IL10 IL13 IL4 IL5
3 immune system MP:0005387 9.83 CCL11 CCL17 CCL5 CCR3 EPX FCER2
4 respiratory system MP:0005388 9.17 CCL11 CCR3 IFNG IL10 IL13 IL4
Sources

Drugs & Therapeutics for Allergic Hypersensitivity Disease

About this section

Drugs for Allergic Hypersensitivity Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1347)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ertapenem Approved, Investigational Phase 4,Not Applicable 153832-46-3 150610
2
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
4
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-82-4 7028
7
Pheniramine Approved Phase 4,Phase 3 86-21-5 4761
8
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
9
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
10
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90566-53-3 62924
11
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 242138-07-4
12
Cyproheptadine Approved Phase 4,Phase 2 129-03-3 2913
13
Capsaicin Approved Phase 4,Phase 3,Phase 2,Not Applicable 404-86-4 1548943
14
Azelastine Approved Phase 4,Phase 3,Not Applicable 58581-89-8 2267
15
Montelukast Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 158966-92-8 5281040
16
Cetirizine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83881-51-0 2678
17
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068
18
Caffeine Approved Phase 4 58-08-2 2519
19
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
20
Clavulanate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58001-44-8 5280980
21
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 443-48-1 4173
22
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 26787-78-0 33613
23
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
24
Indomethacin Approved, Investigational Phase 4,Early Phase 1,Not Applicable 53-86-1 3715
25
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
26
Piperacillin Approved Phase 4,Phase 3,Not Applicable 66258-76-2 43672
27
Sulbactam Approved Phase 4,Phase 3,Phase 2 68373-14-8
28
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137-58-6 3676
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
32
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2,Not Applicable 59467-70-8 4192
33
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
34
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
35
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
36
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
37
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
38
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
41
Enalaprilat Approved Phase 4 76420-72-9 6917719
42
Xylometazoline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 526-36-3 5709
43
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83919-23-7
44
Acyclovir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59277-89-3 2022
45
Tranexamic Acid Approved Phase 4 1197-18-8 5526
46
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
47
Clindamycin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 18323-44-9 29029
48
Povidone Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9003-39-8
49
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
50
Teicoplanin Approved, Investigational Phase 4,Not Applicable 61036-62-2

Interventional clinical trials:

(show top 50) (show all 5466)
# Name Status NCT ID Phase Drugs
1 Safety of Ertapenem in Beta-lactam Allergic Patients. Unknown status NCT01159379 Phase 4 ertapenem
2 Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit? Unknown status NCT01431859 Phase 4
3 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
4 Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy Unknown status NCT02405923 Phase 4
5 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
6 Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma Unknown status NCT00496574 Phase 4
7 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
8 A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography Unknown status NCT02163005 Phase 4 Gadolinium
9 Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS) Unknown status NCT00867737 Phase 4 Advair HFA MDI 115/21;Symbicort 160/4.5 pMDI
10 The Effect of Xolair on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Unknown status NCT00673218 Phase 4 Placebo;Xolair
11 Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects Unknown status NCT00258141 Phase 4 Rupatadine;Placebo
12 Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis Unknown status NCT02014623 Phase 4 Control
13 Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma Unknown status NCT00830505 Phase 4 fluticasone/ salmeterol;fluticasone
14 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
15 Hypervolemia in ESRD Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
16 Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis Unknown status NCT00825656 Phase 4 Sinol or Sinol-M nasal spray
17 AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) Unknown status NCT02238353 Phase 4 azelastine + fluticasone;Placebo
18 Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma. Unknown status NCT01939951 Phase 4
19 Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES) Unknown status NCT00406094 Phase 4 montelukast;placebo
20 Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
21 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis Unknown status NCT00488176 Phase 4 montelukast;cetirizine;montelukast and cetirizine;placebo
22 Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma Unknown status NCT00500253 Phase 4
23 Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia Unknown status NCT01789294 Phase 4 Mesalamine
24 Diverticulitis: Antibiotics or Close Observation? Unknown status NCT01111253 Phase 4 Amoxicillin-clavulanate
25 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
26 Oral Resveratrol to Prevent Post-ERCP Pancreatitis Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
27 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
28 Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Unknown status NCT02057523 Phase 4 Acthar
29 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
30 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
31 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
32 the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation Unknown status NCT02635802 Phase 4 Remifentanil;Lidocaine;Remifentanil+Lidocaine;Midazolam
33 Study of Chlorhexidine as the Hub Antiseptic to Prevent Catheter Related Infections in Newborn Infants Unknown status NCT00516360 Phase 4
34 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
35 4"S" - Seasonal Symptoms Suppression Study Unknown status NCT02557269 Phase 4 Xylometazoline - intranasal application;Azelastine - intranasal application;Mometasone furoate - intranasal application;Hydroxyl-propyl-methyl cellulose powder - intranasal application;Bilastine 20 mg;Prednisolone 5 mg
36 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
37 Effect of HSV-2 Suppressive Therapy on Sexual Behavior Unknown status NCT00495716 Phase 4 acyclovir;acyclovir
38 Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section Unknown status NCT02279186 Phase 4 Tranexamic Acid
39 Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
40 The Amputation Surgical Site Infection Trial (ASSIT) Unknown status NCT02018094 Phase 4 Co-amoxiclav;Iodine;Metronidazole;Chlorhexidine;Teicoplanin;Clindamycin
41 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Completed NCT01618929 Phase 4 Montelukast
42 Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Completed NCT01361347 Phase 4
43 Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy Completed NCT02238210 Phase 4 Atrovent®
44 A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms Completed NCT00637884 Phase 4 Fexofenadine HCl
45 iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Completed NCT02552537 Phase 4 Omeprazole;Placebo
46 Grass Pollen Subcutaneous Immunotherapy in Elderly Patients Completed NCT02440243 Phase 4 Purethal;Purethal -placebo
47 A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy Completed NCT00250263 Phase 4 (agent for immunotherapy) Staloral;Placebo
48 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
49 Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
50 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday

Search NIH Clinical Center for Allergic Hypersensitivity Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hypersensitivity

Sources

Genetic Tests for Allergic Hypersensitivity Disease

About this section
Sources

Anatomical Context for Allergic Hypersensitivity Disease

About this section

MalaCards organs/tissues related to Allergic Hypersensitivity Disease:

42
Testes, Skin, Lung, T Cells, Kidney, Liver, Bone
Sources

Publications for Allergic Hypersensitivity Disease

About this section

Articles related to Allergic Hypersensitivity Disease:

(show top 50) (show all 2818)
# Title Authors Year
1
Characterization of a subgroup of non-type 2 asthma with cow's milk hypersensitivity in young subjects. ( 30834110 )
2019
2
Concomitant hypersensitivity pneumonitis and occupational asthma caused by 2 different etiologic agents. ( 30641195 )
2019
3
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. ( 30649752 )
2019
4
Allergen-specific immunoglobulin E in sera of horses affected with insect bite hypersensitivity, severe equine asthma or both conditions. ( 30520523 )
2019
5
Tactile hypersensitivity and GABA concentration in the sensorimotor cortex of adults with autism. ( 30632707 )
2019
6
Blocking α2δ-1 Subunit Reduces Bladder Hypersensitivity and Inflammation in a Cystitis Mouse Model by Decreasing NF-kB Pathway Activation. ( 30863309 )
2019
7
Ginsenoside Rf relieves mechanical hypersensitivity, depression-like behavior, and inflammatory reactions in chronic constriction injury rats. ( 30740801 )
2019
8
A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. ( 30656750 )
2019
9
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs. ( 30663091 )
2019
10
Facial pustules due to drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms may histopathologically mimic eosinophilic pustular folliculitis: a case report. ( 30666704 )
2019
11
Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome. ( 30670915 )
2019
12
New IgE Immediate Hypersensitivity Reactions Upon Reintroduction of Food Restricted for Treatment of Eosinophilic Esophagitis. ( 30684739 )
2019
13
Systemic growth hormone deficiency causes mechanical and thermal hypersensitivity during early postnatal development. ( 30815617 )
2019
14
Analysis of allergic reaction in IgG4-related disease. ( 30676808 )
2019
15
Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. ( 30413627 )
2019
16
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06. ( 30632847 )
2019
17
Imported Fire Ant Hypersensitivity and Mastocytosis: A Case Series of Successful Venom Immunotherapy. ( 30831255 )
2019
18
Hypersensitivity Myocarditis and Necrotizing Coronary Vasculitis by Clomipramine Causing Steroid-Sensitive Cardiogenic Shock. ( 30744394 )
2019
19
A Novel Desensitization Protocol for Infliximab hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis. ( 30659548 )
2019
20
Cough hypersensitivity in patients with obstructive sleep apnea hypopnea syndrome. ( 29453637 )
2019
21
Chronic urticaria and drug hypersensitivity in children. ( 30830063 )
2019
22
Azathioprine hypersensitivity syndrome in anti-myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30746133 )
2019
23
Widespread mechanical pain hypersensitivity in patients with chronic migraine and temporomandibular disorders: relationship and correlation between psychological and sensorimotor variables. ( 30626243 )
2019
24
Allergic reaction to platelet-rich plasma (PRP): Case report. ( 30855461 )
2019
25
Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy. ( 30915953 )
2019
26
Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. ( 30916737 )
2019
27
Influence of Visual and Vestibular Hypersensitivity on Derealization and Depersonalization in Chronic Dizziness. ( 30814972 )
2019
28
Prevalence of self-reported versus diagnosed dentinal hypersensitivity: a cross-sectional study and ROC curve analysis. ( 30646808 )
2019
29
Diagnosis of occupational hypersensitivity pneumonitis. ( 30649011 )
2019
30
To blow one's trumpet - a musical composition that fits the mould. A case report of Purpureocillium lilacinum causing hypersensitivity pneumonitis in a tenor horn player. ( 30649525 )
2019
31
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. ( 30651100 )
2019
32
Cross-reactivity between halogenated platinum salts in an immediate-type respiratory hypersensitivity model. ( 30654668 )
2019
33
Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007⁻2018. ( 30658389 )
2019
34
Intravenous aspirin challenge as a diagnosis of nonsteroidal anti-inflammatory drugs hypersensitivity. ( 30660169 )
2019
35
Defining and exploiting hypersensitivity hotspots to facilitate abscisic acid receptor agonist optimization. ( 30668093 )
2019
36
Oncogenic basic amino acid insertions at the extracellular juxtamembrane region of IL7Rα cause receptor hypersensitivity. ( 30670441 )
2019
37
Non-Peptidergic Nociceptive Neurons Are Essential for Mechanical Inflammatory Hypersensitivity in Mice. ( 30674034 )
2019
38
Incidence and risk factors of low-osmolar iodinated contrast media related immediate hypersensitivity reactions: A longitudinal study based on a real-time monitoring system. ( 30676320 )
2019
39
Prevalence of Hypersensitivity in Teeth Affected by Molar-Incisor Hypomineralization (MIH). ( 30677762 )
2019
40
The incidence of skin lesions in contrast media-induced chemical hypersensitivity. ( 30679982 )
2019
41
Progesterone hypersensitivity: Case report with favorable evolution. ( 30679983 )
2019
42
Oxaliplatin: Detection and Management of Hypersensitivity Reactions. ( 30682002 )
2019
43
Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice. ( 30682503 )
2019
44
Hypersensitivity Pneumonitis. ( 30684996 )
2019
45
A Targeted Mutation Disrupting Mitochondrial Complex IV Function in Primary Afferent Neurons Leads to Pain Hypersensitivity Through P2Y1 Receptor Activation. ( 30689196 )
2019
46
Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: A population-based cohort study and meta-analysis. ( 30690722 )
2019
47
Multifaceted assessment of dentine hypersensitivity, evaluation of demographic prevalence along with associated factors: A cross-sectional study. ( 30692746 )
2019
48
Unicondylar knee arthroplasty using cobalt-chromium implants in patients with self-reported cutaneous metal hypersensitivity. ( 30700123 )
2019
49
Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone. ( 30704815 )
2019
50
Development and preliminary evaluation of a short self-report measure of generalized pain hypersensitivity. ( 30705605 )
2019
Sources

Variations for Allergic Hypersensitivity Disease

About this section

ClinVar genetic disease variations for Allergic Hypersensitivity Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XX;t(4;14)(p15.2;q13)dn Translocation Likely pathogenic
2 SLC9A6 NM_001042537.1(SLC9A6): c.1346C> A (p.Ala449Glu) single nucleotide variant Uncertain significance rs1556619324 GRCh37 Chromosome X, 135098913: 135098913
3 SLC9A6 NM_001042537.1(SLC9A6): c.1346C> A (p.Ala449Glu) single nucleotide variant Uncertain significance rs1556619324 GRCh38 Chromosome X, 136016754: 136016754
4 GFOD1; MCUR1; NOL7; PHACTR1; RANBP9; RNF182; SIRT5; TBC1D7 GRCh37/hg19 6p24.1-23(chr6: 12536624-13968949) copy number gain Uncertain significance GRCh37 Chromosome 6, 12536624: 13968949
Sources

Expression for Allergic Hypersensitivity Disease

About this section
Search GEO for disease gene expression data for Allergic Hypersensitivity Disease.
Sources

Pathways for Allergic Hypersensitivity Disease

About this section

Pathways related to Allergic Hypersensitivity Disease according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 CCL11 CCL5 EPX FCER2 IFNG IGHE
2
ERK Signaling 65
Show member pathways
 13.86 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
3
PEDF Induced Signaling 65
Show member pathways
 13.71 CCL11 CCL17 CCL5 CCR3 FCER2 HRH4
4
TGF-Beta Pathway 65
Show member pathways
 13.55 CCL11 CCL17 CCL5 IFNG IL10 IL13
5
Akt Signaling 65
Show member pathways
 13.46 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
6
Cytokine Signaling in Immune system 67
Show member pathways
 13.42 CCL11 CCL5 FCER2 IFNG IGHE IL10
7
PAK Pathway 65
Show member pathways
 13.32 CCL11 CCL17 CCL5 CCR3 HRH4 IL10
8
Allograft rejection 1 38
Show member pathways
 12.94 CCL11 EPX IFNG IL10 IL13 IL4
9
CCR5 Pathway in Macrophages 65
Show member pathways
 12.82 CCL11 CCL17 CCL5 CCR3 HRH4
10
Pathways in cancer 38
12.79 IFNG IL13 IL4 IL5 KITLG
11
NF-kappaB Signaling 4
12.6 CCL5 IFNG IL10 IL4 KITLG TPT1
12
Th17 cell differentiation 38
Show member pathways
 12.59 IFNG IL10 IL13 IL4 IL5
13
T cell receptor signaling pathway 38
Show member pathways
 12.45 IFNG IL10 IL4 IL5 IL9
14
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.45 IFNG IL10 IL13 IL4 IL5 IL9
15
Development IGF-1 receptor signaling 23
Show member pathways
 12.42 CCL11 FCER2 HRH1 IGHE IL4
16
IL-17 Family Signaling Pathways 66
Show member pathways
 12.41 CCL11 CCL17 IFNG IL13 IL4 IL5
17
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.34 IFNG IL10 IL13 IL4 IL5 IL9
18
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.08 CCR3 IFNG IL10 IL4 IL5 KITLG
19
Interleukin-4 and 13 signaling 67
12.06 CCL11 FCER2 IGHE IL10 IL13 IL4
20
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 66
Show member pathways
 12.01 CCL11 CCL17 CCL5 CCR3
21